Similar results were reported after the NEI sponsored X-linked retinoschisis trial in which ocular inflammation was reported as the main adverse event following treatment, and the patients’ sera tested positive for neutralizing antibodies against the AAV8 capsid but not the RS1 protein [109]. This evidence concerns the gene RS1 and retinoschisis.